It seems that there have been some significant gastro-intestinal (GI) problems in the Alzheimers trials for Encenicline in the current phase three clinical trials. I wonder if the issue is related to the age of the patients in the trial - something that would not be an issue with most people who have schizophrenia (because they are much younger). We’ll see when more information is announced.
Two fully enrolled Phase 3 efficacy trials evaluating the use of encenicline to treat CIS will continue, with additional vigilance around GI safety monitoring of patients. Top-line results from these trials are anticipated in the first half of 2016.
FORUM was advised that studies investigating the use of encenicline in Alzheimer’s disease (AD) have been placed on clinical hold. A small number of serious gastrointestinal (GI) safety events reported in the AD studies prompted the clinical hold. FORUM has discontinued all study medication in the AD trials and no new patients will be recruited into the studies until the clinical hold is lifted.
More info here: